Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region

The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in the EMBRAZE region. The test identifies which patients are suited for standard cancer treatments, and which patients could benefit from experimental treatments. EMBRAZE is a cancer care network in the provinces of North Brabant and Zeeland.
More information
You read an article in the category Billing code. You may also be interested in Cancer of Unknown Primary, OncoAct or Participating hospitals.All news
Also read

Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …

Whole genome sequencing to improve individual cancer treatment in Finland
Since August 2019, Docrates, a private cancer center in Finland, uses the whole genome sequencing test from Hartwig Medical Foundation to …

Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …

Just one WGS test is enough to reveal everything you need to know to provide a patient with metastatic cancer with targeted treatment, be it a registered therapy or part of a research trial.